NYMC Faculty Publications
DOI
10.21037/atm.2017.11.29
Journal Title
Annals of Translational Medicine
First Page
482
Document Type
Article
Publication Date
12-1-2017
Department
Medicine
Abstract
Background: Data on outcomes of ST-elevation myocardial infarction (STEMI) in patients with cancer are scarce. We investigated the nationwide trends in admissions for STEMI, utilization of percutaneous coronary intervention (PCI), and in-hospital outcomes in patients with the three most common cancer diagnoses (lung, breast, and colon) compared to patients without cancer. Methods: We conducted an administrative database study using the Nationwide Inpatient Sample (NIS). All in-patient hospitalizations for STEMI from 2001 to 2011 were identified. Patients with concomitant diagnosis of lung, breast or colon cancer were identified using appropriate International classification of diagnosis (ICD 9-CM) codes. Primary outcome was utilization of PCI and in-hospital mortality in patients with cancer compared to those without cancer. Results: Utilization of PCI was 30.8% (1,191/3,871), 20.2% (4,541/22,480) and 17.3% (1,716/9,944) in patients with breast, lung and colon cancer, respectively. Among patients without any of these cancers, use of PCI was 49.6%. In-hospital mortality was highest in patients with lung cancer (57.1%) and lowest in patients without cancer (25.7%). Conclusions: Patients with cancer have significantly worse in-hospital mortality compared to those without cancer, partly due to a relatively lower rate of PCI utilization in cancer patients with STEMI.
Recommended Citation
Pothineni, N., Shah, N., Rochlani, Y., Saad, M., Kovelamudi, S., Marmagkiolis, K., Bhatti, S., Cilingiroglu, M., Aronow, W., & Hakeem, A. (2017). Temporal Trends and Outcomes of Acute Myocardial Infarction in Patients With Cancer. Annals of Translational Medicine, 5 (24), 482. https://doi.org/10.21037/atm.2017.11.29
Publisher's Statement
Originally published in Annals of Translational Medicine 2017;5(24):482. The original material can be found here.